Meanwhile, fellow activist Active Ownership Capital--which has been sparring with Stada for months now--has been taking a different tack. It's working to overturn the drugmaker's board, which it hopes to do at Stada's annual meeting late next month. And as for the drugmaker itself, it's hoping to placate investors with a competing slate of board nominees of its own. The way Wyser-Pratte sees it, though, the time to strike is now.